Janus Henderson Group PLC raised its stake in West Pharmaceutical Services Inc. (NYSE:WST) by 27.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 875,723 shares of the medical instruments supplier’s stock after buying an additional 186,752 shares during the quarter. Janus Henderson Group PLC owned about 1.19% of West Pharmaceutical Services worth $86,951,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Integrated Investment Consultants LLC bought a new position in West Pharmaceutical Services in the second quarter valued at approximately $155,000. BlackRock Inc. lifted its stake in West Pharmaceutical Services by 1.4% in the second quarter. BlackRock Inc. now owns 6,570,782 shares of the medical instruments supplier’s stock valued at $652,413,000 after buying an additional 87,586 shares in the last quarter. Private Advisor Group LLC bought a new position in West Pharmaceutical Services in the second quarter valued at approximately $304,000. Mutual of America Capital Management LLC lifted its stake in West Pharmaceutical Services by 5.1% in the second quarter. Mutual of America Capital Management LLC now owns 63,509 shares of the medical instruments supplier’s stock valued at $6,306,000 after buying an additional 3,092 shares in the last quarter. Finally, Mawer Investment Management Ltd. lifted its stake in West Pharmaceutical Services by 14.3% in the second quarter. Mawer Investment Management Ltd. now owns 312,900 shares of the medical instruments supplier’s stock valued at $31,068,000 after buying an additional 39,094 shares in the last quarter. 95.99% of the stock is currently owned by hedge funds and other institutional investors.
NYSE WST opened at $116.18 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.94 and a current ratio of 2.67. West Pharmaceutical Services Inc. has a 12-month low of $82.74 and a 12-month high of $118.05. The company has a market capitalization of $8.61 billion, a PE ratio of 44.51, a price-to-earnings-growth ratio of 3.97 and a beta of 1.20.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.03. West Pharmaceutical Services had a net margin of 8.99% and a return on equity of 15.38%. The company had revenue of $447.50 million for the quarter, compared to the consensus estimate of $422.57 million. During the same period last year, the company earned $0.66 earnings per share. The firm’s revenue was up 12.6% compared to the same quarter last year. analysts predict that West Pharmaceutical Services Inc. will post 2.82 EPS for the current fiscal year.
In other news, SVP Karen Flynn sold 20,458 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $116.23, for a total value of $2,377,833.34. Following the sale, the senior vice president now directly owns 31,051 shares in the company, valued at $3,609,057.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Federici sold 42,869 shares of West Pharmaceutical Services stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $96.09, for a total transaction of $4,119,282.21. Following the completion of the sale, the chief financial officer now owns 270,681 shares in the company, valued at $26,009,737.29. The disclosure for this sale can be found here. Insiders sold 68,327 shares of company stock worth $6,983,316 over the last quarter. 2.70% of the stock is owned by corporate insiders.
A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research note on Wednesday, August 8th. ValuEngine raised shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Tuesday, June 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. West Pharmaceutical Services has a consensus rating of “Hold” and a consensus target price of $108.33.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading: Hedge Funds
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.